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Purpose of the study
To study the durability of different antiretroviral regimens
prescribed as first treatment (naive patients) and the rea-
sons for discontinuation in a cohort of patients from an
urban setting in a developing country.
Methods
Retrospective cohort study. We included a random sample
of patients who attended an HIV clinic in Buenos Aires,
Argentina, and started highly active antiretroviral therapy
(HAART) as first treatment in 1998–2007. All antiretrovi-
ral regimens consisted of lamivudine plus a second
nucleos(t)ide and a third drug which could be a non-nucl-
eoside reverse transcriptase inhibitor (NN), a protease
inhibitor (PI), or other nucleoside (3N). Patients starting
monotherapy, bitherapy or regimens different from those
described above were excluded.
Summary of results
We analyzed data for 123 patients. Mean age (± SD) was
39.8 ± 6.9 years, 92.7% were male. Risk factors were:
74.3% MSM, 21.9% heterosexual, and 3% IVDU. Mean
follow-up was 3.2 ± 2.5 years. At HAART start, mean CD4
count was 264.4 ± 185.7 (180.8 ± 166 for PI group, 294.3
± 176.3 for NN and 385 ± 310.8 for 3N, p = 0.005); mean
viral load was 291,840.6 ± 372,843.3 (517,781 ±
498,755.8; 204,308.8 ± 261,678,2 and 35,550 ±
14,354.3; respectively, p = 0.006). In 399 person-years,
there were 53 treatment changes: 13.4 per 100 patient-
years (CI: 10.7–16.3). Main causes were: toxicity (73.5%),
virologic failure (9.4%), and immunologic failure (4%).
Discontinuation rate (regardless of the drug/s changed) in
NN group was 10.7 (7.8–13.9) per 100 patient-years; and
28.45 (19.8–36.2) per 100 patient-years in the PI group.
Drug-specific discontinuation rate per 100 person-years
was 6.23 for efavirenz, 4.3 for nevirapine, 25.6 for pro-
tease inhibitors, 4.6 for AZT, 20 for d4T, and 0 for abacavir
and tenofovir. Using Kaplan-Meier curves, 50% of the
patients were still on the first regimen at 80 months.
According to treatment group, these figures were 50% at
84 months for NN group (50% at 82 months for efavirenz
and more than 50% at 120 months for nevirapine) and
50% at 22 months for PI group (p < 0.05).
Conclusion
In this population, patients starting with a NN-based reg-
imen show a low rate of treatment change or discontinu-
ation. This regimens proved to be durable and effective
(even in patients starting with high viral loads or low CD4
counts), and have the advantage to be much cheaper than
PI-based regimens, a key issue in developing countries.
Toxicity is by far the most cause common for first treat-
ment discontinuation.
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